Informed Consent Guidance Focuses On Children And Non-English Speaking Subjects
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s draft guidance urges consideration of ethical ramifications of enrolling or excluding potential subjects from clinical trials when there may be a language barrier.
You may also be interested in...
Informed Consent Final Guidance: Drug Makers Get Some Tweaks But Not Every Change They Wanted
From when the consent process starts to how to handle standard of care discussions, US FDA’s long-awaited final guidance on informed consent reflects some changes sought by sponsors. More changes may be in store soon due to revisions of the Common Rule.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.